Polen Capital Management LLC Raises Stake in LeMaitre Vascular Inc (LMAT)

Polen Capital Management LLC grew its position in LeMaitre Vascular Inc (NASDAQ:LMAT) by 33.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,183 shares of the medical instruments supplier’s stock after buying an additional 3,334 shares during the quarter. Polen Capital Management LLC owned 0.07% of LeMaitre Vascular worth $511,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Piedmont Investment Advisors LLC acquired a new stake in shares of LeMaitre Vascular in the second quarter valued at $119,000. Tower Research Capital LLC TRC grew its stake in shares of LeMaitre Vascular by 222.8% in the second quarter. Tower Research Capital LLC TRC now owns 4,451 shares of the medical instruments supplier’s stock valued at $149,000 after buying an additional 3,072 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of LeMaitre Vascular in the second quarter valued at $206,000. First Trust Advisors LP acquired a new stake in shares of LeMaitre Vascular in the third quarter valued at $214,000. Finally, Creative Planning acquired a new stake in shares of LeMaitre Vascular in the second quarter valued at $220,000. 80.90% of the stock is owned by institutional investors and hedge funds.

In related news, Director Michael H. Thomas sold 20,000 shares of the business’s stock in a transaction on Tuesday, October 30th. The stock was sold at an average price of $27.93, for a total transaction of $558,600.00. Following the completion of the transaction, the director now directly owns 20,000 shares of the company’s stock, valued at approximately $558,600. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 20.30% of the company’s stock.

LMAT has been the subject of a number of research reports. ValuEngine cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Monday, July 30th. Zacks Investment Research cut LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Wednesday, August 1st. BidaskClub cut LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Saturday, September 8th. Roth Capital cut LeMaitre Vascular from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $38.00 to $39.00 in a research note on Tuesday, October 2nd. Finally, Lake Street Capital cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, October 5th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $35.86.

LMAT opened at $27.64 on Friday. LeMaitre Vascular Inc has a 12 month low of $25.63 and a 12 month high of $41.28. The firm has a market cap of $541.25 million, a P/E ratio of 26.58, a P/E/G ratio of 2.26 and a beta of 0.99.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Friday, October 5th. The medical instruments supplier reported $0.21 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.21. LeMaitre Vascular had a return on equity of 18.07% and a net margin of 20.52%. The firm had revenue of $24.17 million during the quarter, compared to analysts’ expectations of $26.06 million. Analysts anticipate that LeMaitre Vascular Inc will post 1.02 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 6th. Investors of record on Tuesday, November 20th will be paid a dividend of $0.07 per share. The ex-dividend date of this dividend is Monday, November 19th. This represents a $0.28 annualized dividend and a yield of 1.01%. LeMaitre Vascular’s payout ratio is 32.56%.

TRADEMARK VIOLATION NOTICE: This story was first published by WKRB News and is the property of of WKRB News. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.wkrb13.com/2018/11/25/polen-capital-management-llc-raises-stake-in-lemaitre-vascular-inc-lmat.html.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

See Also: Average Daily Trade Volume – What It Means In Stock Trading

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply